Education
About Us
Working with TipRanks
Follow Us
Telix Pharmaceuticals Ltd. (TLPPF)
OTHER OTC:TLPPF
Total Valuation
Telix Pharmaceuticals has a market cap or net worth of $4.16B. The enterprise value is $8.56B.
Market Cap$4.16B
Enterprise Value$8.56B
Share Statistics
Telix Pharmaceuticals has 338,399,050 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding338,399,050
Owned by Insiders6.64%
Owned by Institutions―
Financial Efficiency
Telix Pharmaceuticals’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 6.06%.
Return on Equity (ROE)0.09
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)6.06%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee1.89M
Profits Per Employee0.00
Employee Count415
Asset Turnover0.52
Inventory Turnover7.17
Valuation Ratios
The current PE Ratio of Telix Pharmaceuticals is 335.8. Telix Pharmaceuticals’s PEG ratio is ―.
PE Ratio335.8
PS Ratio0.00
PB Ratio0.00
Price to Fair Value14.35
Price to FCF0.00
Price to Operating Cash Flow179.98
PEG Ratio―
Income Statement
In the last 12 months, Telix Pharmaceuticals had revenue of 783.21M and earned 49.92M in profits. Earnings per share was 0.15.
Revenue783.21M
Gross Profit509.68M
Operating Income82.13M
Pretax Income56.06M
Net Income49.92M
EBITDA92.55M
Earnings Per Share (EPS)0.15
Cash Flow
In the last 12 months, operating cash flow was 43.03M and capital expenditures -34.03M, giving a free cash flow of 9.00M billion.
Operating Cash Flow43.03M
Free Cash Flow9.00M
Free Cash Flow per Share0.03
Dividends & Yields
Telix Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.41
52-Week Price Change-13.70%
50-Day Moving Average14.06
200-Day Moving Average16.04
Relative Strength Index (RSI)39.32
Average Volume (3m)7.48K
Important Dates
Telix Pharmaceuticals upcoming earnings date is Feb 19, 2026, TBA (Confirmed).
Last Earnings DateAug 20, 2025
Next Earnings DateFeb 19, 2026
Ex-Dividend Date―
Financial Position
Telix Pharmaceuticals as a current ratio of 2.78, with Debt / Equity ratio of 102.33%
Current Ratio2.78
Quick Ratio2.66
Debt to Market Cap0.07
Net Debt to EBITDA-1.39
Interest Coverage Ratio2.25
Taxes
In the past 12 months, Telix Pharmaceuticals has paid 6.14M in taxes.
Income Tax6.14M
Effective Tax Rate0.11
Enterprise Valuation
Telix Pharmaceuticals EV to EBITDA ratio is 86.69, with an EV/FCF ratio of 891.69.
EV to Sales10.24
EV to EBITDA86.69
EV to Free Cash Flow891.69
EV to Operating Cash Flow186.45
Balance Sheet
Telix Pharmaceuticals has $710.35M in cash and marketable securities with $581.45M in debt, giving a net cash position of -$128.90M billion.
Cash & Marketable Securities$710.35M
Total Debt$581.45M
Net Cash-$128.90M
Net Cash Per Share-$0.38
Tangible Book Value Per Share$0.46
Margins
Gross margin is 73.91%, with operating margin of 10.49%, and net profit margin of 6.37%.
Gross Margin73.91%
Operating Margin10.49%
Pretax Margin7.16%
Net Profit Margin6.37%
EBITDA Margin11.82%
EBIT Margin11.82%
Analyst Forecast
The average price target for Telix Pharmaceuticals is $19.79, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$19.79
Price Target Upside77.49% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast―